Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Summary

The main object of this multicenter, randomized, double-blind, placebo-controlled phase III trial is to assess impact of maintenance of orteronel on disease progression and hence on quality of life of patients with metastatic castration resistant prostate cancer pretreated with novel hormonal agents who have non-progressive disease after chemotherapy with a taxane.

Timeline

Start

2014-08-19

Primary completion

2014-08-19

Completion

2034-08-19

Drugs

Indications